niacinamide has been researched along with Cancer of Skin in 142 studies
nicotinamide : A pyridinecarboxamide that is pyridine in which the hydrogen at position 3 is replaced by a carboxamide group.
| Excerpt | Relevance | Reference |
|---|---|---|
| " We assessed the association of somatic mutations with clinicopathologic features and clinical outcomes in patients with metastatic melanoma treated on E2603, comparing treatment with carboplatin, paclitaxel ± sorafenib (CP vs." | 9.19 | Correlation of somatic mutations and clinical outcome in melanoma patients treated with Carboplatin, Paclitaxel, and sorafenib. ( D'Andrea, K; Flaherty, KT; Kirkwood, JM; Kluger, HM; Lee, SJ; Letrero, R; Nathanson, KL; Rimm, DL; Schuchter, LM; Wilson, MA; Zhao, F, 2014) |
| "In a multicenter phase-II-DeCOG study (NCT00623402) in 10 dermato-oncology centers, 55 patients with metastatic melanoma received a combination of sorafenib (2 x 400 mg/day orally) and pegylated interferon alpha-2b (3 μg/kg body weight 1 x/week subcutaneously)." | 9.17 | Cutaneous side effects of combined therapy with sorafenib and pegylated interferon alpha-2b in metastatic melanoma (phase II DeCOG trial). ( Degen, A; Egberts, F; Garbe, C; Gutzmer, R; Hauschild, A; Kilian, K; Poppe, LM; Trefzer, U; Ugurel, S; Weichenthal, M, 2013) |
| "Isolated limb infusion with melphalan (ILI-M) corrected for ideal body weight (IBW) is a well-tolerated treatment for patients with in-transit extremity melanoma with an approximate 29 % complete response (CR) rate." | 9.16 | A phase I multi-institutional study of systemic sorafenib in conjunction with regional melphalan for in-transit melanoma of the extremity. ( Augustine, C; Beasley, GM; Brady, MS; Coleman, AP; Davies, MA; Peterson, BL; Raymond, A; Sanders, G; Selim, MA; Tyler, DS, 2012) |
| "The safety of oral sorafenib up to a maximum protocol-specified dose combined with dacarbazine in patients with metastatic, histologically confirmed melanoma was investigated in a phase I dose-escalation study and the activity of the combination was explored in an open-label phase II study." | 9.15 | Sorafenib and dacarbazine as first-line therapy for advanced melanoma: phase I and open-label phase II studies. ( Affolter, A; Ahmad, T; Chao, D; Chevreau, C; Corrie, P; Eisen, T; Gibbens, I; Gore, ME; Harries, M; James, MG; Jouary, T; Lorigan, P; Marais, R; Montegriffo, E; Nathan, PD; Negrier, S; Ottensmeier, C; Prendergast, S; Robert, C; Strauss, UP, 2011) |
| " Sorafenib, carboplatin, and paclitaxel (SCP) has antitumor activity in melanoma patients, but no association was found between response and activating B-Raf V600E mutations." | 9.14 | Expression of sorafenib targets in melanoma patients treated with carboplatin, paclitaxel and sorafenib. ( Camp, RL; Flaherty, KT; Jilaveanu, L; Kluger, HM; Lee, SJ; Nathanson, KL; Rimm, DL; Zito, C, 2009) |
| "These data suggest that there could be an association between sorafenib therapy and the development of cutaneous SCC and inflammation of AK." | 7.75 | Cutaneous squamous cell carcinoma and inflammation of actinic keratoses associated with sorafenib. ( Dubauskas, Z; Hwu, P; Jonasch, E; Kunishige, J; Prieto, VG; Tannir, NM, 2009) |
| "To report the development of keratoacanthoma (KA)-type squamous cell carcinomas (SCCs) in patients treated with the multikinase inhibitor sorafenib for the treatment of solid tumors, to present the possible mechanisms for induction of these SCCs, and to discuss the implications for discontinuation of therapy and possible cotherapies to decrease this side effect." | 7.75 | Eruptive keratoacanthoma-type squamous cell carcinomas in patients taking sorafenib for the treatment of solid tumors. ( Haley, H; Hamza, S; Skelton, HG; Smith, KJ, 2009) |
| "A 66-year-old man with malignant melanoma was treated with sorafenib, 2 yen 400 mg per day." | 7.75 | Multiple colon ulcerations, perforation and death during treatment of malignant melanoma with sorafenib. ( Frieling, T; Heise, J; Wassilew, SW, 2009) |
| "Sorafenib is an oral multikinase inhibitor that targets 2 classes of kinases which are known to be involved in both tumor proliferation and angiogenesis." | 6.44 | Metastatic melanoma: scientific rationale for sorafenib treatment and clinical results. ( Egberts, F; Hauschild, A; Kahler, KC; Livingstone, E, 2008) |
| "Sorafenib is a multikinase inhibitor that displays antiproliferative and antiangiogenic properties in the treatment of solid tumors." | 5.37 | Eruptive squamous cell carcinomas with keratoacanthoma-like features in a patient treated with sorafenib. ( Adams, DR; Lynch, MC; Straub, R, 2011) |
| " We assessed the association of somatic mutations with clinicopathologic features and clinical outcomes in patients with metastatic melanoma treated on E2603, comparing treatment with carboplatin, paclitaxel ± sorafenib (CP vs." | 5.19 | Correlation of somatic mutations and clinical outcome in melanoma patients treated with Carboplatin, Paclitaxel, and sorafenib. ( D'Andrea, K; Flaherty, KT; Kirkwood, JM; Kluger, HM; Lee, SJ; Letrero, R; Nathanson, KL; Rimm, DL; Schuchter, LM; Wilson, MA; Zhao, F, 2014) |
| "In a multicenter phase-II-DeCOG study (NCT00623402) in 10 dermato-oncology centers, 55 patients with metastatic melanoma received a combination of sorafenib (2 x 400 mg/day orally) and pegylated interferon alpha-2b (3 μg/kg body weight 1 x/week subcutaneously)." | 5.17 | Cutaneous side effects of combined therapy with sorafenib and pegylated interferon alpha-2b in metastatic melanoma (phase II DeCOG trial). ( Degen, A; Egberts, F; Garbe, C; Gutzmer, R; Hauschild, A; Kilian, K; Poppe, LM; Trefzer, U; Ugurel, S; Weichenthal, M, 2013) |
| "Isolated limb infusion with melphalan (ILI-M) corrected for ideal body weight (IBW) is a well-tolerated treatment for patients with in-transit extremity melanoma with an approximate 29 % complete response (CR) rate." | 5.16 | A phase I multi-institutional study of systemic sorafenib in conjunction with regional melphalan for in-transit melanoma of the extremity. ( Augustine, C; Beasley, GM; Brady, MS; Coleman, AP; Davies, MA; Peterson, BL; Raymond, A; Sanders, G; Selim, MA; Tyler, DS, 2012) |
| "The safety of oral sorafenib up to a maximum protocol-specified dose combined with dacarbazine in patients with metastatic, histologically confirmed melanoma was investigated in a phase I dose-escalation study and the activity of the combination was explored in an open-label phase II study." | 5.15 | Sorafenib and dacarbazine as first-line therapy for advanced melanoma: phase I and open-label phase II studies. ( Affolter, A; Ahmad, T; Chao, D; Chevreau, C; Corrie, P; Eisen, T; Gibbens, I; Gore, ME; Harries, M; James, MG; Jouary, T; Lorigan, P; Marais, R; Montegriffo, E; Nathan, PD; Negrier, S; Ottensmeier, C; Prendergast, S; Robert, C; Strauss, UP, 2011) |
| " Sorafenib, carboplatin, and paclitaxel (SCP) has antitumor activity in melanoma patients, but no association was found between response and activating B-Raf V600E mutations." | 5.14 | Expression of sorafenib targets in melanoma patients treated with carboplatin, paclitaxel and sorafenib. ( Camp, RL; Flaherty, KT; Jilaveanu, L; Kluger, HM; Lee, SJ; Nathanson, KL; Rimm, DL; Zito, C, 2009) |
| "Autophagy was measured in tumor biopsies obtained from metastatic melanoma patients enrolled on a phase II trial of temozolomide and sorafenib and correlated to clinical outcome." | 3.77 | Measurements of tumor cell autophagy predict invasiveness, resistance to chemotherapy, and survival in melanoma. ( Amaravadi, RK; Li, LZ; Lum, JJ; Ma, XH; McAfee, QW; Nathanson, KL; Piao, S; Wang, D, 2011) |
| "To report the development of keratoacanthoma (KA)-type squamous cell carcinomas (SCCs) in patients treated with the multikinase inhibitor sorafenib for the treatment of solid tumors, to present the possible mechanisms for induction of these SCCs, and to discuss the implications for discontinuation of therapy and possible cotherapies to decrease this side effect." | 3.75 | Eruptive keratoacanthoma-type squamous cell carcinomas in patients taking sorafenib for the treatment of solid tumors. ( Haley, H; Hamza, S; Skelton, HG; Smith, KJ, 2009) |
| "A 66-year-old man with malignant melanoma was treated with sorafenib, 2 yen 400 mg per day." | 3.75 | Multiple colon ulcerations, perforation and death during treatment of malignant melanoma with sorafenib. ( Frieling, T; Heise, J; Wassilew, SW, 2009) |
| "These data suggest that there could be an association between sorafenib therapy and the development of cutaneous SCC and inflammation of AK." | 3.75 | Cutaneous squamous cell carcinoma and inflammation of actinic keratoses associated with sorafenib. ( Dubauskas, Z; Hwu, P; Jonasch, E; Kunishige, J; Prieto, VG; Tannir, NM, 2009) |
| "Subcutaneous tumours and artificially induced pulmonary metastases of the rhabdomyosarcoma R1H of the rat were treated either with fractionated irradiation alone or in combination with nicotinamide and carbogen." | 3.69 | Combination of fractionated irradiation with nicotinamide and carbogen in R1H-tumours of the rat and its pulmonary metastases. ( Beck-Bornholdt, HP; Krüll, A; Raabe, A; Rett, M, 1997) |
| "Phorbol ester-induced promotion of initiated NMRI mouse skin keratinocytes to papillomas could be largely prevented when nicotinamide-like inhibitors of poly(ADP-ribose)polymerase (nicotinamide, benzamide, 3-aminobenzamide) were applied simultaneously with 12-O-tetradecanoylphorbol-13-acetate (TPA)." | 3.68 | Nicotinamide and nicotinamide analogues as antitumor promoters in mouse skin. ( Dietel, M; Hilz, H; Ludwig, A; Müller, K; Schäfer, G, 1990) |
| "Chemoprophylaxis against nonmelanoma skin cancer (NMSC) should be considered in high-risk populations such as those with certain genetic disorders, immunosuppressive states, chronic radiation, excessive UV exposure, or extensive personal or family history of NMSC." | 3.01 | Preventative Options and the Future of Chemoprevention for Cutaneous Tumors. ( Anderson, JM; Moy, L; Moy, RL, 2023) |
| "The vitamin B3 deficiency in skin cancer patients was positively correlated with the expressions of HIF-1α and p53." | 2.90 | Correlation of changes in HIF-1α and p53 expressions with vitamin B3 deficiency in skin cancer patients. ( Liu, T; Mou, Y; Yang, H; Zhang, H, 2019) |
| "Patients with metastatic CM who are treated with the MEK inhibitor pimasertib are at high risk of development of ocular adverse events including serous retinopathy and possibly RVO, stressing the need of adequate ophthalmological follow-up including OCT during administration of pimasertib, despite the fact that SRF generally does not lead to ophthalmological complaints." | 2.87 | Pimasertib-associated ophthalmological adverse events. ( Boon, CJF; Jager, MJ; Kruit, WHJ; Luyten, GPM; van Dijk, EHC; Vingerling, JR, 2018) |
| "Nonmelanoma skin cancers, such as basal-cell carcinoma and squamous-cell carcinoma, are common cancers that are caused principally by ultraviolet (UV) radiation." | 2.80 | A Phase 3 Randomized Trial of Nicotinamide for Skin-Cancer Chemoprevention. ( Chen, AC; Chinniah, N; Choy, B; Dalziell, RA; Damian, DL; Dhillon, HM; Fernández-Peñas, P; Halliday, GM; Kricker, A; Martin, AJ; McKenzie, CA; Scolyer, RA; St George, G; Vardy, JL, 2015) |
| " The lack of standardized dosing and standardized outcome measures makes comparison across existing studies challenging, and the lack of adverse events reporting in the majority of studies limits analysis of supplement safety." | 2.72 | Dietary supplements in dermatology: A review of the evidence for zinc, biotin, vitamin D, nicotinamide, and Polypodium. ( Kim, N; Thompson, KG, 2021) |
| "The incidence of skin cancer has gradually increased in the last years and exposition to ultraviolet radiation remains the main risk factor." | 2.72 | Oral nicotinamide: The role in skin cancer chemoprevention. ( Bortoluzzi, P; Giacalone, S; Nazzaro, G; Spigariolo, CB, 2021) |
| "Moreover, NAM reduces skin cancer incidence and prevents the immune-suppressive effects of UV in mice." | 2.61 | Role of Nicotinamide in Genomic Stability and Skin Cancer Chemoprevention. ( Abeni, D; Campione, E; Candi, E; Dellambra, E; Fania, L; Mazzanti, C, 2019) |
| "Chemoprevention of nonmelanoma skin cancer should be considered in patients likely to develop numerous, invasive, or metastatic nonmelanoma skin cancers." | 2.61 | Topical and Systemic Modalities for Chemoprevention of Nonmelanoma Skin Cancer. ( Council, ML; Nemer, KM, 2019) |
| "The incidence of non-melanoma skin cancer (NMSC) is dramatically increasing worldwide, despite the increased use of improved sunscreens." | 2.61 | Skin cancer prevention: a review of current topical options complementary to sunscreens. ( Chipps, L; Herrmann, J; Rosenthal, A; Stoddard, M, 2019) |
| "Ocular adverse events appeared early in the treatment." | 2.52 | Ocular Toxicity in Metastatic Melanoma Patients Treated With Mitogen-Activated Protein Kinase Kinase Inhibitors: A Case Series. ( Alessio, G; Guida, M; Niro, A; Recchimurzo, N; Sborgia, L; Strippoli, S, 2015) |
| "The use of topical nicotinamide in the treatment of acne vulgaris; melasma; atopic dermatitis; rosacea; and oral nicotinamide in preventing nonmelanoma skin cancer is discussed." | 2.50 | A review of nicotinamide: treatment of skin diseases and potential side effects. ( Rolfe, HM, 2014) |
| "We observed more cases of skin cancer during sorafenib treatment than during sunitinib treatment for advanced RCC; median MKI treatment duration before the identification of skin cancer was longer than 1 year." | 2.49 | Skin cancer associated with the use of sorafenib and sunitinib for renal cell carcinoma. ( Breaker, K; Flaig, IP; Flaig, TW; La Rosa, FG; Naam, M, 2013) |
| "Sorafenib is a newly developed multitargeted protein kinase inhibitor reported to induce a variety of adverse cutaneous effects, rarely including actinic keratoses, keratocanthomas, and squamous cell carcinomas (SCCs)." | 2.47 | Sorafenib-induced premalignant and malignant skin lesions. ( Cohen, PR; Stewart, DJ; Williams, VL, 2011) |
| "Skin cancer is by far the most common malignancy in Caucasian populations, and additional strategies to reduce the morbidity and economic burden of this disease are now urgently needed." | 2.46 | Photoprotective effects of nicotinamide. ( Damian, DL, 2010) |
| "Sorafenib is an oral multikinase inhibitor that targets 2 classes of kinases which are known to be involved in both tumor proliferation and angiogenesis." | 2.44 | Metastatic melanoma: scientific rationale for sorafenib treatment and clinical results. ( Egberts, F; Hauschild, A; Kahler, KC; Livingstone, E, 2008) |
| "Approved for the treatment of advanced renal cell carcinoma by the US FDA and other regulatory agencies, sorafenib is an agent with multiple targets that may also prove beneficial in other malignancies." | 2.44 | Sorafenib: delivering a targeted drug to the right targets. ( Flaherty, KT, 2007) |
| "To characterize oral skin cancer chemoprophylaxis education for acitretin and nicotinamide among current MSDO fellows and to compare the clinical indications felt most appropriate for prescribing to a previously published expert consensus." | 1.91 | Education and Perspectives on the Use of Oral Skin Cancer Chemoprophylaxis: A Cross-Sectional Survey of Current Fellows in Mohs Micrographic Surgery & Dermatologic Oncology. ( Guzman, AK; Ruiz, ES; Schmults, CD, 2023) |
| "Cutaneous immune-related adverse events (irAEs) occur in more than one-third of patients treated with immune checkpoint inhibitors; they are often the first clinical manifestation, although they may occur months after initiation of therapy." | 1.72 | Cutaneous immune-related adverse events and photodamaged skin in patients with metastatic melanoma: could nicotinamide be useful? ( Colombo, J; Covarelli, P; De Giorgi, V; Doni, L; Silvestri, F; Stanganelli, I; Trane, L; Venturi, F; Zuccaro, B, 2022) |
| "Sorafenib is a multikinase inhibitor increasingly used for the treatment of several solid tumors." | 1.62 | Penile and scrotal infundibular cysts in an adolescent treated with sorafenib. ( Colmenero, I; Hernández-Martín, Á; Martos-Cabrera, L; Mateos-Mayo, A; Ramírez-Lluch, M; Torrelo, A, 2021) |
| "Skin cancer is among the most common cancers worldwide and identifiable molecular changes for early and late stage of skin tumorigenesis can suggest the better targets for its control." | 1.43 | Preventive effects of butyric acid, nicotinamide, calcium glucarate alone or in combination during the 7, 12-dimethylbenz (a) anthracene induced mouse skin tumorigenesis via modulation of K-Ras-PI3K-AKTpathway and associated micro RNAs. ( Gupta, KP; Pandey, M; Qadri, SS; Sahay, S; Tiwari, P, 2016) |
| "Cutaneous melanoma is a significant cause of morbidity and mortality." | 1.40 | Nicotinamide enhances repair of ultraviolet radiation-induced DNA damage in primary melanocytes. ( Damian, DL; Halliday, GM; Surjana, D; Thompson, BC, 2014) |
| "Melanoma is highly metastatic, but the mechanism of melanoma cell migration is still unclear." | 1.40 | SIRT1 regulates lamellipodium extension and migration of melanoma cells. ( Hayashi, T; Hirobe, T; Hisahara, S; Horimoto, K; Horio, Y; Jimbow, K; Kunimoto, R; Sato, M; Sugino, T; Tanimura, A; Yamashita, T, 2014) |
| "Metastatic melanoma is associated with a splicing switch to pro-angiogenic VEGF-A, previously shown to be regulated by SRSF1 phosphorylation by SRPK1." | 1.40 | Targeting SRPK1 to control VEGF-mediated tumour angiogenesis in metastatic melanoma. ( Bates, DO; Coupland, SE; Dean, R; Gammons, MV; Lucas, R; Oltean, S, 2014) |
| "A primary culture of renal cell carcinoma cells (KMRM-S2) was established from an advanced renal cell carcinoma patient with cutaneous metastasis, who had not responded to sorafenib." | 1.39 | Expression of angiogenesis-related gene profiles and development of resistance to tyrosine-kinase inhibitor in advanced renal cell carcinoma: characterization of sorafenib-resistant cells derived from a cutaneous metastasis. ( Ashida, S; Fukuhara, H; Inoue, K; Kamada, M; Karashima, T; Kuroda, N; Shuin, T; Taguchi, T; Tamura, K, 2013) |
| "The emergence of skin tumors in patients treated with sorafenib or with more recent BRAF inhibitors is an intriguing and potentially serious event." | 1.38 | Skin tumors induced by sorafenib; paradoxic RAS-RAF pathway activation and oncogenic mutations of HRAS, TP53, and TGFBR1. ( André, J; Arnault, JP; Boussemart, L; Druillennec, S; Dumaz, N; Eggermont, AM; Escudier, B; Eychène, A; Hollville, E; Kamsu-Kom, N; Lacroix, L; Larcher, M; Malka, D; Mateus, C; Robert, C; Sarasin, A; Soria, JC; Spatz, A; Tomasic, G; Vagner, S; Wechsler, J, 2012) |
| "Cotreatment with sorafenib and diclofenac interrupts a positive feedback signaling loop involving extracellular signal-regulated kinase, cellular phospholipase A2, and COX." | 1.38 | Synthetic lethal screening with small-molecule inhibitors provides a pathway to rational combination therapies for melanoma. ( Axelrod, M; Capaldo, BJ; Gioeli, D; Jensen, K; Mackey, A; Roller, DG; Weber, MJ, 2012) |
| "Sorafenib is a multikinase inhibitor approved for the treatment of renal cell carcinoma and hepatocellular carcinoma." | 1.37 | [Squamous cell carcinoma in a patient receiving sorafenib]. ( Adnot-Desanlis, L; Bernard, P; Reguiaï, Z, 2011) |
| "Sorafenib is a multikinase inhibitor that displays antiproliferative and antiangiogenic properties in the treatment of solid tumors." | 1.37 | Eruptive squamous cell carcinomas with keratoacanthoma-like features in a patient treated with sorafenib. ( Adams, DR; Lynch, MC; Straub, R, 2011) |
| "Cutaneous melanoma is a tumor with rising incidence and a very poor prognosis at the disseminated stage." | 1.37 | Fibroblast growth factor receptors as therapeutic targets in human melanoma: synergism with BRAF inhibition. ( Bedeir, A; Berger, W; Ghassemi, S; Grasl-Kraupp, B; Grusch, M; Heffeter, P; Heinzle, C; Held, G; Holzmann, K; Marian, B; Metzner, T; Micksche, M; Peter-Vörösmarty, B; Pirker, C; Spiegl-Kreinecker, S, 2011) |
| "Sorafenib is a multikinase inhibitor newly approved for the treatment of renal cell carcinoma and hepatocellular carcinoma." | 1.35 | The histologic spectrum of epithelial neoplasms induced by sorafenib. ( Jaworsky, C; Kish, LS; Kwon, EJ, 2009) |
| "Sorafenib is a new multikinase inhibitor recently approved for renal cell carcinoma and hepatocarcinoma." | 1.35 | [Eruptive nevi associated with sorafenib treatment]. ( Bennani-Lahlou, M; Escudier, B; Massard, C; Mateus, C; Robert, C; Soria, JC; Spatz, A, 2008) |
| "She had no history of skin cancer." | 1.35 | Multiple squamous cell carcinomas of the skin after therapy with sorafenib combined with tipifarnib. ( Cohen, PR; Diwan, AH; Evans, HL; Hong, DS; Kurzrock, R; Prieto, VG; Reddy, SB; Tannir, NM; Wright, JJ, 2008) |
| "The incidence of skin cancer continues to increase despite increased use of sunscreens, which are less effective at preventing immunosuppression than sunburn." | 1.35 | UV radiation-induced immunosuppression is greater in men and prevented by topical nicotinamide. ( Barnetson, RS; Damian, DL; Halliday, GM; Park, J; Patterson, CR; Stapelberg, M, 2008) |
| "The combined treatment of melanoma cells with sorafenib and rapamycin led to an approximately twofold increase of cell death compared with sorafenib monotreatment (P<0." | 1.35 | Combined inhibition of MAPK and mTOR signaling inhibits growth, induces cell death, and abrogates invasive growth of melanoma cells. ( Flaherty, KT; Garbe, C; Kulms, D; Lasithiotakis, KG; Maczey, E; Meier, FE; Schittek, B; Sinnberg, TW, 2008) |
| "Cutaneous metastases from renal cell carcinoma (RCC) are uncommon, but may be painful and deforming." | 1.34 | Complete response in a cutaneous facial metastatic nodule from renal cell carcinoma after hypofractionated radiotherapy. ( Allison, RR; Cavalieri, R; Finley, J; Gay, HA; Quan, WD, 2007) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (0.70) | 18.7374 |
| 1990's | 5 (3.52) | 18.2507 |
| 2000's | 25 (17.61) | 29.6817 |
| 2010's | 85 (59.86) | 24.3611 |
| 2020's | 26 (18.31) | 2.80 |
| Authors | Studies |
|---|---|
| Hunt, SV | 1 |
| Jamison, A | 1 |
| Malhotra, R | 1 |
| De Giorgi, V | 1 |
| Colombo, J | 1 |
| Trane, L | 1 |
| Silvestri, F | 1 |
| Venturi, F | 1 |
| Zuccaro, B | 1 |
| Doni, L | 1 |
| Stanganelli, I | 1 |
| Covarelli, P | 1 |
| Moreira, GA | 2 |
| Caetano, MMM | 1 |
| do Vale, JA | 1 |
| de Paiva, JC | 1 |
| Gonçalves, VHS | 2 |
| Almeida, AA | 1 |
| Silva, LVG | 1 |
| Martim, FRG | 1 |
| de Andrade Barros, MV | 1 |
| Guimarães, GR | 1 |
| de Oliveira Santos, L | 1 |
| de Souza, APM | 2 |
| Machado-Neves, M | 2 |
| Teixeira, RR | 2 |
| Silva-Júnior, A | 1 |
| Fietto, JLR | 2 |
| Boroni, M | 1 |
| de Oliveira, LL | 1 |
| Bressan, GC | 2 |
| Anderson, JM | 3 |
| Moy, L | 3 |
| Moy, RL | 3 |
| Allen, NC | 2 |
| Martin, AJ | 10 |
| Snaidr, VA | 2 |
| Eggins, R | 1 |
| Chong, AH | 1 |
| Fernandéz-Peñas, P | 3 |
| Gin, D | 1 |
| Sidhu, S | 1 |
| Paddon, VL | 1 |
| Banney, LA | 1 |
| Lim, A | 1 |
| Upjohn, E | 1 |
| Schaider, H | 1 |
| Ganhewa, AD | 1 |
| Nguyen, J | 1 |
| McKenzie, CA | 5 |
| Prakash, S | 1 |
| McLean, C | 1 |
| Lochhead, A | 1 |
| Ibbetson, J | 1 |
| Dettrick, A | 1 |
| Landgren, A | 1 |
| Allnutt, KJ | 1 |
| Allison, C | 1 |
| Davenport, RB | 1 |
| Mumford, BP | 1 |
| Wong, B | 1 |
| Stagg, B | 1 |
| Tedman, A | 1 |
| Gribbin, H | 1 |
| Edwards, HA | 1 |
| De Rosa, N | 1 |
| Stewart, T | 1 |
| Doolan, BJ | 1 |
| Kok, Y | 1 |
| Simpson, K | 1 |
| Low, ZM | 1 |
| Kovitwanichkanont, T | 1 |
| Scolyer, RA | 6 |
| Dhillon, HM | 3 |
| Vardy, JL | 3 |
| Chadban, SJ | 1 |
| Bowen, DG | 1 |
| Chen, AC | 9 |
| Damian, DL | 20 |
| Schmults, CD | 2 |
| Jambusaria-Pahlajani, A | 2 |
| Ruiz, E | 1 |
| Trepanowski, N | 1 |
| Kim, DY | 1 |
| Hartman, RI | 2 |
| Boeri, M | 1 |
| Skelsey, MK | 1 |
| Schiro, JA | 1 |
| Dozier, SE | 1 |
| Glinert, R | 1 |
| Okun, MM | 1 |
| Riddle, AO | 1 |
| Guzman, AK | 1 |
| Ruiz, ES | 2 |
| Fania, L | 1 |
| Mazzanti, C | 1 |
| Campione, E | 1 |
| Candi, E | 1 |
| Abeni, D | 1 |
| Dellambra, E | 1 |
| Malesu, R | 1 |
| Lyons, JG | 2 |
| Madore, J | 2 |
| Halliday, GM | 14 |
| Gollins, CE | 1 |
| Shah, A | 1 |
| Sinha, K | 1 |
| Khan, S | 1 |
| Paul, N | 1 |
| Meeajun, B | 1 |
| Abbott, RA | 1 |
| Blasdale, C | 1 |
| Cooper, H | 1 |
| Harwood, CA | 1 |
| Ismail, F | 1 |
| Lear, JT | 1 |
| Mackintosh, L | 1 |
| McCormack, S | 1 |
| Perrett, CM | 1 |
| Proby, CM | 1 |
| Durack, A | 1 |
| Patalay, R | 1 |
| Matin, RN | 1 |
| Paugam, C | 1 |
| Dréno, B | 1 |
| Thompson, KG | 1 |
| Kim, N | 1 |
| Tee, LY | 1 |
| Sultana, R | 1 |
| Tam, SYC | 1 |
| Oh, CC | 1 |
| Vale, JAD | 1 |
| Lima, GDA | 1 |
| Barros, MVA | 1 |
| Pereira, WL | 1 |
| Merchid, NCLE | 1 |
| Chen, CC | 2 |
| Chen, YY | 1 |
| Lo, YH | 1 |
| Lin, MH | 1 |
| Chang, CH | 1 |
| Chen, CL | 1 |
| Wang, HE | 1 |
| Wu, CY | 1 |
| Scatozza, F | 1 |
| Moschella, F | 1 |
| D'Arcangelo, D | 1 |
| Rossi, S | 1 |
| Tabolacci, C | 1 |
| Giampietri, C | 1 |
| Proietti, E | 1 |
| Facchiano, F | 1 |
| Facchiano, A | 1 |
| Huber, R | 1 |
| Wong, A | 1 |
| Mateos-Mayo, A | 1 |
| Colmenero, I | 1 |
| Ramírez-Lluch, M | 1 |
| Martos-Cabrera, L | 1 |
| Hernández-Martín, Á | 1 |
| Torrelo, A | 1 |
| Hoegler, KM | 1 |
| Khachemoune, A | 1 |
| Arzeno, J | 1 |
| Leavitt, E | 1 |
| Lonowski, S | 1 |
| Kim, J | 1 |
| Giacalone, S | 1 |
| Spigariolo, CB | 1 |
| Bortoluzzi, P | 1 |
| Nazzaro, G | 1 |
| Knackstedt, TJ | 1 |
| Knackstedt, RW | 1 |
| Djohan, M | 1 |
| Djohan, R | 1 |
| Gastman, BR | 1 |
| Crowe, DR | 1 |
| Desai, S | 1 |
| Olbricht, S | 1 |
| Drago, F | 2 |
| Ciccarese, G | 2 |
| Cogorno, L | 1 |
| Calvi, C | 1 |
| Marsano, LA | 1 |
| Parodi, A | 2 |
| Lim, SY | 1 |
| Menzies, AM | 1 |
| Rizos, H | 1 |
| Minocha, R | 2 |
| Arenberger, P | 1 |
| Arenbergerova, M | 1 |
| Nazarali, S | 1 |
| Kuzel, P | 1 |
| Nestor, L | 1 |
| Clowry, J | 1 |
| Molloy, K | 1 |
| Connolly, M | 1 |
| Salim, A | 1 |
| Tobin, AM | 1 |
| Liu, T | 1 |
| Yang, H | 1 |
| Mou, Y | 1 |
| Zhang, H | 1 |
| Blomberg, M | 1 |
| He, SY | 1 |
| Harwood, C | 1 |
| Arron, ST | 1 |
| Demehri, S | 1 |
| Green, A | 1 |
| Asgari, MM | 1 |
| Gilmore, SJ | 2 |
| van Dijk, EHC | 1 |
| Kruit, WHJ | 1 |
| Jager, MJ | 1 |
| Luyten, GPM | 1 |
| Vingerling, JR | 1 |
| Boon, CJF | 1 |
| Phelan, PS | 1 |
| Ballotti, R | 3 |
| Healy, E | 1 |
| Bertolotto, C | 1 |
| Rosenthal, A | 1 |
| Stoddard, M | 1 |
| Chipps, L | 1 |
| Herrmann, J | 1 |
| Nemer, KM | 1 |
| Council, ML | 1 |
| Verhave, B | 1 |
| Goldberg, M | 1 |
| Hashim, P | 1 |
| Levitt, J | 1 |
| Azad, N | 1 |
| Yu, M | 1 |
| Davidson, B | 1 |
| Choyke, P | 1 |
| Wood, BJ | 1 |
| Venkatesan, A | 1 |
| Henning, R | 1 |
| Calvo, K | 1 |
| Minasian, L | 1 |
| Edelman, DC | 1 |
| Meltzer, P | 1 |
| Steinberg, SM | 1 |
| Annunziata, CM | 1 |
| Kohn, EC | 1 |
| Breaker, K | 1 |
| Naam, M | 1 |
| La Rosa, FG | 1 |
| Flaig, IP | 1 |
| Flaig, TW | 1 |
| El Tal, AK | 1 |
| Remichofsky, CJ | 1 |
| Mehregan, DA | 1 |
| Ganger, LK | 1 |
| Bahadoran, P | 2 |
| Allegra, M | 2 |
| Le Duff, F | 1 |
| Long-Mira, E | 1 |
| Hofman, P | 1 |
| Giacchero, D | 1 |
| Passeron, T | 1 |
| Lacour, JP | 1 |
| Degen, A | 2 |
| Weichenthal, M | 1 |
| Ugurel, S | 1 |
| Trefzer, U | 1 |
| Kilian, K | 1 |
| Garbe, C | 3 |
| Egberts, F | 2 |
| Poppe, LM | 1 |
| Hauschild, A | 4 |
| Gutzmer, R | 2 |
| Botton, T | 1 |
| Yeh, I | 1 |
| Nelson, T | 1 |
| Vemula, SS | 1 |
| Sparatta, A | 1 |
| Garrido, MC | 1 |
| Rocchi, S | 1 |
| McCalmont, TH | 1 |
| LeBoit, PE | 1 |
| Burton, EA | 1 |
| Bollag, G | 1 |
| Bastian, BC | 1 |
| Vin, H | 1 |
| Ching, G | 1 |
| Ojeda, SS | 1 |
| Adelmann, CH | 1 |
| Chitsazzadeh, V | 1 |
| Dwyer, DW | 1 |
| Ma, H | 1 |
| Ehrenreiter, K | 1 |
| Baccarini, M | 1 |
| Ruggieri, R | 1 |
| Curry, JL | 1 |
| Ciurea, AM | 1 |
| Duvic, M | 1 |
| Busaidy, NL | 1 |
| Tannir, NM | 3 |
| Tsai, KY | 1 |
| Kunimoto, R | 1 |
| Jimbow, K | 1 |
| Tanimura, A | 1 |
| Sato, M | 1 |
| Horimoto, K | 1 |
| Hayashi, T | 1 |
| Hisahara, S | 1 |
| Sugino, T | 1 |
| Hirobe, T | 1 |
| Yamashita, T | 1 |
| Horio, Y | 1 |
| Wilson, MA | 1 |
| Zhao, F | 1 |
| Letrero, R | 1 |
| D'Andrea, K | 1 |
| Rimm, DL | 3 |
| Kirkwood, JM | 1 |
| Kluger, HM | 3 |
| Lee, SJ | 2 |
| Schuchter, LM | 1 |
| Flaherty, KT | 4 |
| Nathanson, KL | 3 |
| Thompson, BC | 1 |
| Surjana, D | 3 |
| Gammons, MV | 1 |
| Lucas, R | 1 |
| Dean, R | 1 |
| Coupland, SE | 1 |
| Oltean, S | 1 |
| Bates, DO | 1 |
| Fathi, AT | 1 |
| Lin, WM | 1 |
| Durazzo, T | 1 |
| Piris, A | 2 |
| Sadrzadeh, H | 1 |
| Bernardo, L | 1 |
| Borger, DR | 1 |
| McAfee, SL | 1 |
| Kroshinsky, D | 1 |
| Chen, YB | 1 |
| Rolfe, HM | 1 |
| Tiwari, P | 2 |
| Sahay, S | 2 |
| Pandey, M | 2 |
| Qadri, SS | 2 |
| Gupta, KP | 3 |
| Kim, B | 1 |
| de León, FJ | 1 |
| Blanes, MM | 1 |
| Albares, MP | 1 |
| Berbegal, L | 1 |
| Niro, A | 1 |
| Strippoli, S | 1 |
| Alessio, G | 1 |
| Sborgia, L | 1 |
| Recchimurzo, N | 1 |
| Guida, M | 1 |
| Djokovic, D | 1 |
| Trindade, A | 1 |
| Gigante, J | 1 |
| Pinho, M | 1 |
| Harris, AL | 1 |
| Duarte, A | 1 |
| Choy, B | 1 |
| Dalziell, RA | 3 |
| Kricker, A | 1 |
| St George, G | 1 |
| Chinniah, N | 1 |
| Sidaway, P | 1 |
| Bagcchi, S | 1 |
| Hajdenberg, J | 1 |
| Okano, S | 1 |
| Zhao, Y | 1 |
| Lowe, PM | 1 |
| Eris, JM | 1 |
| Bielski, VA | 1 |
| Grunwald, MR | 1 |
| McDonnell, MH | 1 |
| Induru, R | 1 |
| Gerber, JM | 1 |
| Escudero-Góngora, MM | 1 |
| Yélamos, O | 1 |
| Halpern, AC | 1 |
| Weinstock, MA | 1 |
| Forbat, E | 1 |
| Al-Niaimi, F | 1 |
| Ali, FR | 1 |
| Hong, DS | 1 |
| Reddy, SB | 1 |
| Prieto, VG | 2 |
| Wright, JJ | 1 |
| Cohen, PR | 2 |
| Diwan, AH | 1 |
| Evans, HL | 1 |
| Kurzrock, R | 1 |
| Kong, HH | 1 |
| Sibaud, V | 2 |
| Chanco Turner, ML | 1 |
| Fojo, T | 1 |
| Hornyak, TJ | 1 |
| Chevreau, C | 2 |
| Kahler, KC | 1 |
| Livingstone, E | 1 |
| Ardavanis, A | 1 |
| Doufexis, D | 1 |
| Kountourakis, P | 1 |
| Rigatos, G | 1 |
| Melnikova, VO | 1 |
| Bar-Eli, M | 1 |
| Lopez, V | 1 |
| Pinazo, I | 1 |
| Marti, N | 1 |
| Monteagudo, C | 1 |
| Jorda, E | 1 |
| Bennani-Lahlou, M | 1 |
| Mateus, C | 3 |
| Escudier, B | 3 |
| Massard, C | 1 |
| Soria, JC | 3 |
| Spatz, A | 3 |
| Robert, C | 5 |
| Poust, J | 1 |
| Jilaveanu, L | 1 |
| Zito, C | 1 |
| Camp, RL | 2 |
| Arbiser, JL | 1 |
| Dubauskas, Z | 1 |
| Kunishige, J | 1 |
| Jonasch, E | 1 |
| Hwu, P | 1 |
| Yang, J | 1 |
| Zaja-Milatovic, S | 1 |
| Thu, YM | 1 |
| Lee, F | 1 |
| Smykla, R | 1 |
| Richmond, A | 1 |
| Frieling, T | 1 |
| Heise, J | 1 |
| Wassilew, SW | 1 |
| Arnault, JP | 2 |
| Wechsler, J | 2 |
| Tomasic, G | 2 |
| Aractingi, S | 1 |
| Grange, JD | 1 |
| Poirier-Colame, V | 1 |
| Malka, D | 2 |
| Smith, KJ | 1 |
| Haley, H | 1 |
| Hamza, S | 1 |
| Skelton, HG | 1 |
| Kwon, EJ | 1 |
| Kish, LS | 1 |
| Jaworsky, C | 1 |
| Spector, E | 1 |
| Franklin, MJ | 1 |
| Truskinovsky, AM | 1 |
| Dudek, AZ | 1 |
| Jilaveanu, LB | 1 |
| Zito, CR | 1 |
| Aziz, SA | 1 |
| Conrad, PJ | 1 |
| Schmitz, JC | 1 |
| Sznol, M | 1 |
| Sivapirabu, G | 1 |
| Yiasemides, E | 1 |
| Park, J | 2 |
| Donghi, D | 1 |
| Dummer, R | 1 |
| Cozzio, A | 1 |
| Wellbrock, C | 1 |
| Hurlstone, A | 1 |
| Handolias, D | 1 |
| Hamilton, AL | 1 |
| Salemi, R | 1 |
| Tan, A | 1 |
| Moodie, K | 1 |
| Kerr, L | 1 |
| Dobrovic, A | 1 |
| McArthur, GA | 2 |
| Satzger, I | 1 |
| Voelker, B | 1 |
| Kapp, A | 1 |
| Niessner, H | 1 |
| Beck, D | 1 |
| Sinnberg, T | 1 |
| Lasithiotakis, K | 1 |
| Maczey, E | 2 |
| Gogel, J | 1 |
| Venturelli, S | 1 |
| Berger, A | 1 |
| Mauthe, M | 1 |
| Toulany, M | 1 |
| Flaherty, K | 1 |
| Schaller, M | 1 |
| Schadendorf, D | 2 |
| Proikas-Cezanne, T | 1 |
| Schittek, B | 2 |
| Kulms, D | 2 |
| Meier, F | 1 |
| Denoyer, D | 1 |
| Potdevin, T | 1 |
| Roselt, P | 1 |
| Neels, OC | 1 |
| Kirby, L | 1 |
| Greguric, I | 1 |
| Katsifis, A | 1 |
| Dorow, DS | 1 |
| Hicks, RJ | 1 |
| Raymond, AK | 1 |
| Puri, PK | 1 |
| Selim, MA | 2 |
| Tyler, DS | 2 |
| Nelson, KC | 1 |
| Donaldson, MR | 1 |
| Stetson, CL | 1 |
| Smith, JL | 1 |
| Ma, XH | 1 |
| Piao, S | 1 |
| Wang, D | 1 |
| McAfee, QW | 1 |
| Lum, JJ | 1 |
| Li, LZ | 1 |
| Amaravadi, RK | 1 |
| Adnot-Desanlis, L | 1 |
| Bernard, P | 1 |
| Reguiaï, Z | 1 |
| Lynch, MC | 1 |
| Straub, R | 1 |
| Adams, DR | 1 |
| Williams, VL | 1 |
| Stewart, DJ | 1 |
| El-Gamal, MI | 1 |
| Jung, MH | 1 |
| Lee, WS | 1 |
| Sim, T | 1 |
| Yoo, KH | 1 |
| Oh, CH | 1 |
| Boulinguez, S | 1 |
| Eisen, T | 1 |
| Marais, R | 1 |
| Affolter, A | 1 |
| Lorigan, P | 1 |
| Corrie, P | 1 |
| Ottensmeier, C | 1 |
| Chao, D | 1 |
| Nathan, PD | 1 |
| Jouary, T | 1 |
| Harries, M | 1 |
| Negrier, S | 1 |
| Montegriffo, E | 1 |
| Ahmad, T | 1 |
| Gibbens, I | 1 |
| James, MG | 1 |
| Strauss, UP | 1 |
| Prendergast, S | 1 |
| Gore, ME | 1 |
| Metzner, T | 1 |
| Bedeir, A | 1 |
| Held, G | 1 |
| Peter-Vörösmarty, B | 1 |
| Ghassemi, S | 1 |
| Heinzle, C | 1 |
| Spiegl-Kreinecker, S | 1 |
| Marian, B | 1 |
| Holzmann, K | 1 |
| Grasl-Kraupp, B | 1 |
| Pirker, C | 1 |
| Micksche, M | 1 |
| Berger, W | 1 |
| Heffeter, P | 1 |
| Grusch, M | 1 |
| Oberholzer, PA | 1 |
| Kee, D | 1 |
| Dziunycz, P | 1 |
| Sucker, A | 1 |
| Kamsukom, N | 1 |
| Jones, R | 1 |
| Roden, C | 1 |
| Chalk, CJ | 1 |
| Ardlie, K | 1 |
| Palescandolo, E | 1 |
| MacConaill, LE | 1 |
| Hofbauer, GF | 1 |
| Garraway, LA | 1 |
| Hollville, E | 1 |
| Sarasin, A | 1 |
| Larcher, M | 1 |
| André, J | 1 |
| Kamsu-Kom, N | 1 |
| Boussemart, L | 1 |
| Lacroix, L | 1 |
| Eggermont, AM | 1 |
| Druillennec, S | 1 |
| Vagner, S | 1 |
| Eychène, A | 1 |
| Dumaz, N | 1 |
| Moloney, FJ | 1 |
| Tamiya, H | 1 |
| Kamo, R | 1 |
| Kumei, A | 1 |
| Yanagihara, S | 1 |
| Ishii, M | 1 |
| Kobayashi, H | 1 |
| Masunaga, S | 1 |
| Sakurai, Y | 1 |
| Tanaka, H | 1 |
| Suzuki, M | 1 |
| Liu, Y | 1 |
| Kondo, N | 1 |
| Maruhashi, A | 1 |
| Kinashi, Y | 1 |
| Ono, K | 1 |
| Beasley, GM | 1 |
| Coleman, AP | 1 |
| Raymond, A | 1 |
| Sanders, G | 1 |
| Peterson, BL | 1 |
| Brady, MS | 1 |
| Davies, MA | 1 |
| Augustine, C | 1 |
| Lucas, LM | 1 |
| Svoboda, RM | 1 |
| Mackay, D | 1 |
| Welsch, MJ | 1 |
| Anderson, BE | 1 |
| Ono, S | 1 |
| Tanioka, M | 1 |
| Fujisawa, A | 1 |
| Tanizaki, H | 1 |
| Miyachi, Y | 1 |
| Matsumura, Y | 1 |
| Roller, DG | 1 |
| Axelrod, M | 1 |
| Capaldo, BJ | 1 |
| Jensen, K | 1 |
| Mackey, A | 1 |
| Weber, MJ | 1 |
| Gioeli, D | 1 |
| Karashima, T | 1 |
| Fukuhara, H | 1 |
| Tamura, K | 1 |
| Ashida, S | 1 |
| Kamada, M | 1 |
| Inoue, K | 1 |
| Taguchi, T | 1 |
| Kuroda, N | 1 |
| Shuin, T | 1 |
| Patterson, CR | 1 |
| Stapelberg, M | 1 |
| Barnetson, RS | 1 |
| Gay, HA | 1 |
| Cavalieri, R | 1 |
| Allison, RR | 1 |
| Finley, J | 1 |
| Quan, WD | 1 |
| Lasithiotakis, KG | 1 |
| Sinnberg, TW | 1 |
| Meier, FE | 1 |
| Peters, NA | 1 |
| Richel, DJ | 1 |
| Verhoeff, JJ | 1 |
| Stalpers, LJ | 1 |
| Raabe, A | 1 |
| Rett, M | 1 |
| Krüll, A | 1 |
| Beck-Bornholdt, HP | 1 |
| Gensler, HL | 1 |
| Stüben, G | 1 |
| Stuschke, M | 1 |
| Knühmann, K | 1 |
| Horsman, MR | 1 |
| Sack, H | 1 |
| Chen, B | 1 |
| Zupkó, I | 1 |
| de Witte, PA | 1 |
| Ludwig, A | 1 |
| Dietel, M | 1 |
| Schäfer, G | 1 |
| Müller, K | 1 |
| Hilz, H | 1 |
| Carruthers, C | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Detection of Plasmatic Cell-free BRAF and NRAS Mutations: a New Tool for Monitoring Patients With Metastatic Malignant Melanoma Treated With Targeted Therapies or Immunotherapy ( MALT )[NCT03493230] | 35 participants (Anticipated) | Interventional | 2018-04-30 | Not yet recruiting | |||
| A Phase II, Multi-center, Open-label, Uncontrolled Study to Evaluate the Efficacy and Safety of BAY 43-9006 Given Daily in Combination With Repeated 21-Day Cycles of Dacarbazine (DTIC) Chemotherapy in Subjects With Advanced Metastatic Melanoma.[NCT00492297] | Phase 2 | 83 participants (Actual) | Interventional | 2005-04-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Duration of complete response was the number of days from the date that a complete response was first documented to the date that recurrent or progressive disease was first objectively documented (if patient progressed then censored=no) or to last observation (if patient did not progress then censored=yes). (NCT00492297)
Timeframe: from confirmed CR until PD (median 259 days)
| Intervention | days (Number) |
|---|---|
| Sorafenib + Dacarbazine | 420 |
Duration of partial response was the number of days from the date that a partial response was first documented to the date that recurrent or progressive disease was first objectively documented (if patient progressed then censored=no) or to last observation (if patient did not progress then censored=yes). (NCT00492297)
Timeframe: from confirmed PR until PD (median 259 days)
| Intervention | days (Median) |
|---|---|
| Sorafenib + Dacarbazine | 255 |
Duration of Response was assessed in subjects who showed a Partial Response (PR) or Complete Response (CR). It was defined as the time from the first documented objective response to Progressive Disease (PD), or death if before documented progression. Duration of response for subjects who have not progressed or died at the time of analysis was censored at the date of last tumor assessment. (NCT00492297)
Timeframe: from confirmed Complete Response (CR) or Partial Response (PR) until Progressive Disease (PD) (median 259 days)
| Intervention | days (Median) |
|---|---|
| Sorafenib + Dacarbazine | 327 |
Duration of Stable Disease (DSD), defined as the time from the first documented objective evidence of Stable Disease (SD) to disease progression (DP) or death if death occurred before DP, was assessed in subjects who showed SD as best response. DSD for subjects who had not progressed or died was censored at the date of last tumor assessment. (NCT00492297)
Timeframe: from start of therapy to PD, only in non-responders (median 259 days)
| Intervention | days (Median) |
|---|---|
| Sorafenib + Dacarbazine | 93 |
Overall Survival was the number of days from the date that combination treatment started until the date of death. (NCT00492297)
Timeframe: from start of treatment until death (median 259 days)
| Intervention | days (Median) |
|---|---|
| Sorafenib + Dacarbazine | 259 |
Progression-free Survival (PFS) was the time from the first dose of combination therapy to disease progression (radiological or clinical, whichever is earlier) or death (if death occurs before progression is documented). PFS for subjects without tumor progression or death at the time of analysis were censored at the date of last tumor evaluation. (NCT00492297)
Timeframe: from start of treatment until progression or death before progression (median 259 days)
| Intervention | days (Median) |
|---|---|
| Sorafenib + Dacarbazine | 102 |
Time to Progression was the number of days from the start of therapy to progression (if patient progressed then censored=no) or to the last observation at which the patient was known to have not progressed, that is, the last observation with a best response of CR, PR, or SD. (NCT00492297)
Timeframe: From start of treatment until progression (median 259 days)
| Intervention | days (Median) |
|---|---|
| Sorafenib + Dacarbazine | 102 |
Time to Response in subjects who achieved an objective response (PR or CR with confirmation) was measured from the date of starting study combination treatment until the earliest date that the response was first documented. (NCT00492297)
Timeframe: start of therapy to confirmed CR or PR (median 259 days)
| Intervention | days (Median) |
|---|---|
| Sorafenib + Dacarbazine | 48 |
DC was defined as the total number of subjects whose best response was not progressive disease (PD) (total number of CRs + total number of PRs + total number of Stable Diseases (SD)). The DC at specific time points could also be calculated as the total number of subjects whose response was not PD at that time point. (NCT00492297)
Timeframe: after start of treatment, at 6 months and 12 months
| Intervention | participants (Number) | ||
|---|---|---|---|
| DC based on overall best response | DC at 6 months | DC at 12 months | |
| Sorafenib + Dacarbazine | 41 | 38 | 38 |
Best Overall Response (BOR): Best tumor response achieved during or within 30 days after active therapy confirmed according to the Response Evaluation Criteria in Solid Tumors (RECIST). Complete response (CR): The disappearance of all target and non-target lesions. Partial response (PR): At least a 30% decrease in the sum of the longest diameter (LD) of target lesions, taking as reference the baseline sum LD. SD was defined as steady state of disease, PD was defined as an increase of at least 20% increase in the sum of the LD of target lesions or appearance of new lesions. (NCT00492297)
Timeframe: during or within 30 days after active therapy
| Intervention | participants (Number) | ||||
|---|---|---|---|---|---|
| Overall response (CR+PR) | Complete response (CR) | Partial response (PR) | Stable disease (SD) | Progressive disease (PD) | |
| Sorafenib + Dacarbazine | 10 | 1 | 9 | 31 | 34 |
Progression-free Survival (PFS) was the time from the first dose of combination therapy to disease progression (radiological or clinical, whichever is earlier) or death (if death occurs before progression is documented). PFS for subjects without tumor progression or death at the time of analysis were censored at the date of last tumor evaluation. (NCT00492297)
Timeframe: from start of treatment until progression or death before progression after 3, 6 and 12 months
| Intervention | percentage of participants (Number) | ||
|---|---|---|---|
| PFS at month 3 | PFS at month 6 | PFS at month 12 | |
| Sorafenib + Dacarbazine | 56.63 | 33.73 | 10.84 |
31 reviews available for niacinamide and Cancer of Skin
| Article | Year |
|---|---|
Oral nicotinamide for non-melanoma skin cancers: A review.
Topics: Humans; Keratosis, Actinic; Niacinamide; Research Design; Skin Neoplasms | 2023 |
Preventative Options and the Future of Chemoprevention for Cutaneous Tumors.
Topics: Chemoprevention; Hedgehog Proteins; Humans; Niacinamide; Retinoids; Skin Neoplasms | 2023 |
Preventative Options and the Future of Chemoprevention for Cutaneous Tumors.
Topics: Chemoprevention; Hedgehog Proteins; Humans; Niacinamide; Retinoids; Skin Neoplasms | 2023 |
Preventative Options and the Future of Chemoprevention for Cutaneous Tumors.
Topics: Chemoprevention; Hedgehog Proteins; Humans; Niacinamide; Retinoids; Skin Neoplasms | 2023 |
Preventative Options and the Future of Chemoprevention for Cutaneous Tumors.
Topics: Chemoprevention; Hedgehog Proteins; Humans; Niacinamide; Retinoids; Skin Neoplasms | 2023 |
Preventative Options and the Future of Chemoprevention for Cutaneous Tumors.
Topics: Chemoprevention; Hedgehog Proteins; Humans; Niacinamide; Retinoids; Skin Neoplasms | 2023 |
Preventative Options and the Future of Chemoprevention for Cutaneous Tumors.
Topics: Chemoprevention; Hedgehog Proteins; Humans; Niacinamide; Retinoids; Skin Neoplasms | 2023 |
Preventative Options and the Future of Chemoprevention for Cutaneous Tumors.
Topics: Chemoprevention; Hedgehog Proteins; Humans; Niacinamide; Retinoids; Skin Neoplasms | 2023 |
Preventative Options and the Future of Chemoprevention for Cutaneous Tumors.
Topics: Chemoprevention; Hedgehog Proteins; Humans; Niacinamide; Retinoids; Skin Neoplasms | 2023 |
Preventative Options and the Future of Chemoprevention for Cutaneous Tumors.
Topics: Chemoprevention; Hedgehog Proteins; Humans; Niacinamide; Retinoids; Skin Neoplasms | 2023 |
Role of Nicotinamide in Genomic Stability and Skin Cancer Chemoprevention.
Topics: Animals; Energy Metabolism; Genomic Instability; Humans; Immunosuppression Therapy; NAD; Niacinamide | 2019 |
Dietary supplements in dermatology: A review of the evidence for zinc, biotin, vitamin D, nicotinamide, and Polypodium.
Topics: Biotin; Dietary Supplements; Humans; Niacinamide; Phytotherapy; Polypodium; Skin Diseases; Skin Neop | 2021 |
Chemoprevention of keratinocyte carcinoma and actinic keratosis in solid-organ transplant recipients: Systematic review and meta-analyses.
Topics: Acitretin; Carcinoma, Basal Cell; Carcinoma, Squamous Cell; Humans; Keratosis, Actinic; Niacinamide; | 2021 |
Oral nicotinamide: The role in skin cancer chemoprevention.
Topics: Chemoprevention; Humans; Niacinamide; Skin; Skin Neoplasms; Ultraviolet Rays | 2021 |
New Developments in the Management of Cutaneous Squamous Cell Carcinoma.
Topics: Antineoplastic Agents; Carcinoma, Squamous Cell; Chemoprevention; Chemotherapy, Adjuvant; Humans; Ly | 2021 |
Nicotinamide for skin cancer chemoprevention.
Topics: Carcinoma, Basal Cell; Carcinoma, Squamous Cell; DNA Repair; Humans; Immune Tolerance; Keratosis, Ac | 2017 |
Mechanisms and strategies to overcome resistance to molecularly targeted therapy for melanoma.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Com | 2017 |
Melanoma and nonmelanoma skin cancer chemoprevention: A role for nicotinamide?
Topics: Animals; Carcinoma, Basal Cell; Carcinoma, Squamous Cell; DNA Repair; Humans; Immunomodulation; Mela | 2018 |
New and current preventive treatment options in actinic keratosis.
Topics: Carcinoma, Squamous Cell; Disease Progression; Female; Humans; Keratosis, Actinic; Male; Niacinamide | 2017 |
Vitamin B Derivative (Nicotinamide)Appears to Reduce Skin Cancer Risk.
Topics: Humans; Niacinamide; Risk; Skin Neoplasms; Vitamin B Complex | 2017 |
Research gaps in the management and prevention of cutaneous squamous cell carcinoma in organ transplant recipients.
Topics: Antimetabolites, Antineoplastic; Capecitabine; Carcinoma, Squamous Cell; Health Behavior; Humans; Im | 2017 |
Nicotinamide for photoprotection and skin cancer chemoprevention: A review of efficacy and safety.
Topics: Adenosine Triphosphate; Animals; Anti-Inflammatory Agents; Chemoprevention; Dermatology; DNA Damage; | 2019 |
Skin cancer prevention: a review of current topical options complementary to sunscreens.
Topics: Administration, Cutaneous; Carcinoma, Basal Cell; Carcinoma, Squamous Cell; Cyclooxygenase 2 Inhibit | 2019 |
Topical and Systemic Modalities for Chemoprevention of Nonmelanoma Skin Cancer.
Topics: Administration, Cutaneous; Administration, Oral; Antineoplastic Agents; Carcinoma, Basal Cell; Carci | 2019 |
Skin cancer associated with the use of sorafenib and sunitinib for renal cell carcinoma.
Topics: Adult; Antineoplastic Agents; Carcinoma, Basal Cell; Carcinoma, Renal Cell; Carcinoma, Squamous Cell | 2013 |
Nicotinamide and the skin.
Topics: Acne Vulgaris; Animals; Autoimmune Diseases; Carcinogenesis; Dermatitis, Atopic; Humans; Keratosis, | 2014 |
A review of nicotinamide: treatment of skin diseases and potential side effects.
Topics: Acne Vulgaris; Administration, Cutaneous; Administration, Oral; Chemical and Drug Induced Liver Inju | 2014 |
Ocular Toxicity in Metastatic Melanoma Patients Treated With Mitogen-Activated Protein Kinase Kinase Inhibitors: A Case Series.
Topics: Aged; Female; Humans; Male; Melanoma; Melanoma, Cutaneous Malignant; Middle Aged; Mitogen-Activated | 2015 |
[New molecular target therapy for thyroid neoplasms and malignant melanomas].
Topics: Antibodies, Monoclonal; Antineoplastic Agents; Clinical Trials as Topic; Humans; Indoles; Ipilimumab | 2015 |
Cutaneous manifestations in leukemia patients.
Topics: Adenine Nucleotides; Antineoplastic Agents; Arabinonucleosides; Clofarabine; Cytarabine; Dermatomyco | 2016 |
Nicotinamide: New Indications in Dermatology.
Topics: Carcinoma, Basal Cell; Carcinoma, Squamous Cell; Chemoprevention; Clinical Trials, Phase III as Topi | 2016 |
Use of nicotinamide in dermatology.
Topics: Acne Vulgaris; Dermatitis, Atopic; Humans; Niacinamide; Pigmentation Disorders; Pruritus; Skin Disea | 2017 |
Metastatic melanoma: scientific rationale for sorafenib treatment and clinical results.
Topics: Antineoplastic Agents; Benzenesulfonates; Clinical Trials as Topic; Evidence-Based Medicine; Humans; | 2008 |
BRAF as therapeutic target in melanoma.
Topics: Antineoplastic Agents; Benzenesulfonates; Humans; Melanoma; Niacinamide; Phenylurea Compounds; Proto | 2010 |
Photoprotective effects of nicotinamide.
Topics: Animals; Dermatology; Humans; Immune Tolerance; Niacinamide; Poly(ADP-ribose) Polymerase Inhibitors; | 2010 |
Does basal cell carcinoma belong to the spectrum of sorafenib-induced epithelial skin cancers?
Topics: Aged; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Basal Cell; Carcinoma, Renal Cell; Female | 2010 |
Sorafenib-induced premalignant and malignant skin lesions.
Topics: Antineoplastic Agents; Benzenesulfonates; Humans; Niacinamide; Phenylurea Compounds; Precancerous Co | 2011 |
[Clinical studies with sorafenib (Nexavar) in metastatic melanoma].
Topics: Antineoplastic Agents; Benzenesulfonates; Clinical Trials as Topic; Humans; Melanoma; Niacinamide; P | 2007 |
Sorafenib: delivering a targeted drug to the right targets.
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Carcinoma, Renal Cell; Clinical | 2007 |
18 trials available for niacinamide and Cancer of Skin
| Article | Year |
|---|---|
Nicotinamide for Skin-Cancer Chemoprevention in Transplant Recipients.
Topics: Antineoplastic Agents; Australia; Carcinoma, Basal Cell; Carcinoma, Squamous Cell; Chemoprevention; | 2023 |
Patients' willingness to accept adverse event and cost tradeoffs from oral nicotinamide for reduced risk of non-melanoma skin cancer.
Topics: Adult; Aged; COVID-19; Female; Humans; Logistic Models; Male; Niacinamide; Pandemics; Skin Neoplasms | 2023 |
Prevention of non-melanoma skin cancers with nicotinamide in transplant recipients: a case-control study.
Topics: Carcinoma, Squamous Cell; Case-Control Studies; Female; Humans; Keratosis, Actinic; Kidney Transplan | 2017 |
Nicotinamide for prevention of nonmelanoma skin cancers: a change in practice?
Topics: Carcinoma, Basal Cell; Carcinoma, Squamous Cell; Cost of Illness; Humans; Keratosis, Actinic; Niacin | 2017 |
Correlation of changes in HIF-1α and p53 expressions with vitamin B3 deficiency in skin cancer patients.
Topics: Administration, Oral; Gene Expression Regulation, Neoplastic; Humans; Hypoxia-Inducible Factor 1, al | 2019 |
Pimasertib-associated ophthalmological adverse events.
Topics: Aged; Antineoplastic Agents; Color Perception Tests; Cross-Sectional Studies; Drug-Related Side Effe | 2018 |
A Reduction in Inflammatory Macrophages May Contribute to Skin Cancer Chemoprevention by Nicotinamide.
Topics: Carcinogenesis; Carcinoma, Basal Cell; Carcinoma, Squamous Cell; Cell Count; Humans; Incidence; Macr | 2019 |
Translational predictive biomarker analysis of the phase 1b sorafenib and bevacizumab study expansion cohort.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab; Biomarkers, Phar | 2013 |
Cutaneous side effects of combined therapy with sorafenib and pegylated interferon alpha-2b in metastatic melanoma (phase II DeCOG trial).
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Causality; Comorbidity; Drug Eruptions; Female | 2013 |
Correlation of somatic mutations and clinical outcome in melanoma patients treated with Carboplatin, Paclitaxel, and sorafenib.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carboplatin; Double-Blind | 2014 |
A Phase 3 Randomized Trial of Nicotinamide for Skin-Cancer Chemoprevention.
Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Basal Cell; Carcinoma, Squamous Cell; Double-Blind Method | 2015 |
A phase II randomized controlled trial of nicotinamide for skin cancer chemoprevention in renal transplant recipients.
Topics: Administration, Oral; Adult; Aged; Anticarcinogenic Agents; Carcinoma, Squamous Cell; Chemopreventio | 2016 |
Oral nicotinamide reduces transepidermal water loss: a randomized controlled trial.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Double-Blind Method; Dr | 2016 |
Expression of sorafenib targets in melanoma patients treated with carboplatin, paclitaxel and sorafenib.
Topics: Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Carboplatin; Cell Line, Tumor; Di | 2009 |
Topical nicotinamide modulates cellular energy metabolism and provides broad-spectrum protection against ultraviolet radiation-induced immunosuppression in humans.
Topics: Administration, Topical; Adult; Aged; Animals; Apoptosis; Cells, Cultured; Dose-Response Relationshi | 2009 |
Sorafenib and dacarbazine as first-line therapy for advanced melanoma: phase I and open-label phase II studies.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Dacarbazine; Disease | 2011 |
Oral nicotinamide reduces actinic keratoses in phase II double-blinded randomized controlled trials.
Topics: Aged; Aged, 80 and over; Carcinoma, Basal Cell; Carcinoma, Squamous Cell; Cell Transformation, Neopl | 2012 |
A phase I multi-institutional study of systemic sorafenib in conjunction with regional melphalan for in-transit melanoma of the extremity.
Topics: Antineoplastic Combined Chemotherapy Protocols; Extremities; Female; Follow-Up Studies; Humans; Male | 2012 |
93 other studies available for niacinamide and Cancer of Skin
| Article | Year |
|---|---|
Cutaneous immune-related adverse events and photodamaged skin in patients with metastatic melanoma: could nicotinamide be useful?
Topics: Humans; Immunotherapy; Melanoma; Neoplasms, Second Primary; Niacinamide; Retrospective Studies; Skin | 2022 |
The SRPK inhibitor N-(2-(piperidin-1-yl)-5-(trifluoromethyl)phenyl) isonicotinamide (SRPIN340) increases the immune response against metastatic melanoma in mice.
Topics: Animals; Humans; Immunity; Melanoma; Mice; Niacinamide; Piperidines; Protein Serine-Threonine Kinase | 2022 |
Nicotinamide for Skin-Cancer Chemoprevention in Transplantation.
Topics: Carcinoma, Basal Cell; Chemoprevention; Humans; Niacinamide; Skin Neoplasms; Transplant Recipients | 2023 |
Nicotinamide for Skin-Cancer Chemoprevention in Transplantation.
Topics: Carcinoma, Basal Cell; Chemoprevention; Humans; Niacinamide; Skin Neoplasms; Transplant Recipients | 2023 |
Nicotinamide for Skin-Cancer Chemoprevention in Transplantation. Reply.
Topics: Carcinoma, Basal Cell; Chemoprevention; Humans; Niacinamide; Skin Neoplasms; Transplant Recipients | 2023 |
Nicotinamide for skin cancer chemoprevention in transplant recipients: a critically appraised topic.
Topics: Chemoprevention; Humans; Niacinamide; Organ Transplantation; Skin Neoplasms; Transplant Recipients | 2023 |
Education and Perspectives on the Use of Oral Skin Cancer Chemoprophylaxis: A Cross-Sectional Survey of Current Fellows in Mohs Micrographic Surgery & Dermatologic Oncology.
Topics: Acitretin; Cross-Sectional Studies; Curriculum; Education, Medical, Graduate; Educational Status; Fe | 2023 |
Nicotinamide for skin cancer chemoprevention: effects of nicotinamide on melanoma in vitro and in vivo.
Topics: CD4-Positive T-Lymphocytes; CD8-Positive T-Lymphocytes; Cell Line, Tumor; Cell Movement; Cell Surviv | 2020 |
Feasibility of a trial to evaluate nicotinamide for chemoprevention of skin cancers in organ transplant recipients in the UK.
Topics: Chemoprevention; Feasibility Studies; Humans; Niacinamide; Organ Transplantation; Skin Neoplasms; Tr | 2020 |
Is nicotinamide a sustainable therapy for resistant actinic keratoses?
Topics: Humans; Keratosis, Actinic; Niacinamide; Skin Neoplasms | 2020 |
Effect of the topical administration of N-(2-(4-bromophenylamino)-5-(trifluoromethyl)phenyl)nicotinamide compound in a murine subcutaneous melanoma model.
Topics: Administration, Topical; Animals; Caspase 3; Cell Death; Male; Melanoma, Experimental; Mice; Mice, I | 2020 |
Evaluation of Radioiodinated Fluoronicotinamide/Fluoropicolinamide-Benzamide Derivatives as Theranostic Agents for Melanoma.
Topics: Animals; Benzamides; Cell Line, Tumor; Humans; Iodine Radioisotopes; Melanins; Melanoma, Experimenta | 2020 |
Nicotinamide inhibits melanoma in vitro and in vivo.
Topics: Aged; Animals; Apoptosis; Cell Cycle; Cell Proliferation; Female; Humans; In Vitro Techniques; Male; | 2020 |
Nicotinamide: An Update and Review of Safety & Differences from Niacin.
Topics: Administration, Oral; Dietary Supplements; Humans; Niacinamide; Skin Neoplasms; Vitamin B Complex | 2020 |
Penile and scrotal infundibular cysts in an adolescent treated with sorafenib.
Topics: Adolescent; Carcinoma, Squamous Cell; Humans; Male; Niacinamide; Phenylurea Compounds; Skin Neoplasm | 2021 |
Is the first-line systemic chemoprevention of nonmelanoma skin cancer nicotinamide or acitretin?
Topics: Acitretin; Chemoprevention; Humans; Niacinamide; Skin Neoplasms | 2021 |
Current Practices for Preventative Interventions for Nonmelanoma Skin Cancers Among Dermatologic Surgeons.
Topics: Acitretin; Carcinoma, Basal Cell; Carcinoma, Squamous Cell; Dermatologic Agents; Humans; Institution | 2021 |
Nicotinamide for Keratinocyte Carcinoma Chemoprevention: A Nationwide Survey of Mohs Surgeons.
Topics: Chemoprevention; Humans; Keratinocytes; Mohs Surgery; Niacinamide; Practice Patterns, Physicians'; R | 2021 |
Nicotinamide and skin cancer chemoprevention: The jury is still out.
Topics: Bayes Theorem; Carcinoma, Basal Cell; Carcinoma, Squamous Cell; Clinical Trials, Phase III as Topic; | 2018 |
Chemopreventive potential of nicotinamide in Gilmore's Bayesian analysis.
Topics: Bayes Theorem; Humans; Niacinamide; Skin Neoplasms | 2018 |
Response to 'Considering the chemopreventive potential of nicotinamide in Gilmore's Bayesian analysis'.
Topics: Bayes Theorem; Chemoprevention; Humans; Niacinamide; Skin; Skin Neoplasms | 2018 |
Nicotinamide as a chemopreventive therapy of skin cancers. Too much of good thing?
Topics: Chemoprevention; Humans; NAD; Niacinamide; Signal Transduction; Skin Neoplasms | 2019 |
Treatment of Arsenic-Induced Bowen’s Disease With Topical 5-Fluorouracil
Topics: Administration, Cutaneous; Administration, Oral; Antimetabolites, Antineoplastic; Arsenic; Bowen's D | 2019 |
Multiple squamous cell carcinomas following treatment with sorafenib for renal cell carcinoma.
Topics: Aged; Carcinoma, Renal Cell; Carcinoma, Squamous Cell; Humans; Kidney Neoplasms; Male; Neoplasms, Se | 2013 |
Major clinical response to a BRAF inhibitor in a patient with a BRAF L597R-mutated melanoma.
Topics: Aged; Antineoplastic Agents; Arginine; Back; Cell Survival; Enzyme Activation; Extracellular Signal- | 2013 |
Recurrent BRAF kinase fusions in melanocytic tumors offer an opportunity for targeted therapy.
Topics: Adolescent; Adult; Child, Preschool; Enzyme Activation; Female; Gene Rearrangement; Humans; Indoles; | 2013 |
Sorafenib suppresses JNK-dependent apoptosis through inhibition of ZAK.
Topics: Antineoplastic Agents; Apoptosis; Carcinoma, Squamous Cell; Cell Line, Tumor; Cell Proliferation; Ce | 2014 |
SIRT1 regulates lamellipodium extension and migration of melanoma cells.
Topics: Animals; Cell Movement; Female; Gene Expression Regulation, Neoplastic; Melanoma; Melanoma, Experime | 2014 |
Nicotinamide enhances repair of ultraviolet radiation-induced DNA damage in primary melanocytes.
Topics: Cell Line, Tumor; Cell Survival; Cells, Cultured; DNA Damage; DNA Repair; Humans; Melanocytes; Melan | 2014 |
Targeting SRPK1 to control VEGF-mediated tumour angiogenesis in metastatic melanoma.
Topics: Angiogenesis Inhibitors; Animals; Cell Line, Tumor; Gene Knockdown Techniques; Humans; Melanoma; Mic | 2014 |
Extensive Squamous Cell Carcinoma of the Skin Related to Use of Sorafenib for Treatment of FLT3-Mutant Acute Myeloid Leukemia.
Topics: Aged; Antineoplastic Agents; Carcinoma, Squamous Cell; fms-Like Tyrosine Kinase 3; Humans; Leukemia, | 2016 |
Combinatorial chemopreventive effect of butyric acid, nicotinamide and calcium glucarate against the 7,12-dimethylbenz(a)anthracene induced mouse skin tumorigenesis attained by enhancing the induction of intrinsic apoptotic events.
Topics: 9,10-Dimethyl-1,2-benzanthracene; Animals; Anticarcinogenic Agents; Apoptosis; Apoptotic Protease-Ac | 2015 |
Oral nicotinamide and actinic keratosis: a supplement success story.
Topics: Administration, Oral; Animals; Antineoplastic Agents; Dietary Supplements; DNA Repair; Humans; Immun | 2015 |
Cutaneous metastasis from hepatocellular carcinoma after a percutaneous interventional procedure.
Topics: Adult; Antineoplastic Agents; Carcinoma, Hepatocellular; Combined Modality Therapy; Diathermy; Ethan | 2015 |
Incomplete Dll4/Notch signaling inhibition promotes functional angiogenesis supporting the growth of skin papillomas.
Topics: Adaptor Proteins, Signal Transducing; Animals; Antineoplastic Agents; Calcium-Binding Proteins; Dise | 2015 |
Skin cancer: Nicotinamide reduces new skin cancer risk.
Topics: Carcinoma, Basal Cell; Carcinoma, Squamous Cell; Female; Humans; Keratosis, Actinic; Male; Niacinami | 2016 |
Nicotinamide yields impressive results in skin cancer.
Topics: Administration, Oral; Anticarcinogenic Agents; Humans; Neoplasm Recurrence, Local; Niacinamide; Rand | 2015 |
Preventive effects of butyric acid, nicotinamide, calcium glucarate alone or in combination during the 7, 12-dimethylbenz (a) anthracene induced mouse skin tumorigenesis via modulation of K-Ras-PI3K-AKTpathway and associated micro RNAs.
Topics: 9,10-Dimethyl-1,2-benzanthracene; Animals; Antineoplastic Agents; Blotting, Western; Butyric Acid; G | 2016 |
ACP Journal Club. In high-risk patients, oral nicotinamide reduced number of new nonmelanoma skin cancers during treatment.
Topics: Carcinoma, Basal Cell; Carcinoma, Squamous Cell; Female; Humans; Keratosis, Actinic; Male; Niacinami | 2016 |
Nicotinamide for Skin-Cancer Chemoprevention.
Topics: Carcinoma, Basal Cell; Carcinoma, Squamous Cell; Female; Humans; Keratosis, Actinic; Male; Niacinami | 2016 |
Nicotinamide for Skin-Cancer Chemoprevention.
Topics: Carcinoma, Basal Cell; Carcinoma, Squamous Cell; Female; Humans; Keratosis, Actinic; Male; Niacinami | 2016 |
Nicotinamide for Skin-Cancer Chemoprevention.
Topics: Carcinoma, Basal Cell; Carcinoma, Squamous Cell; Female; Humans; Keratosis, Actinic; Male; Niacinami | 2016 |
Reply to 'A phase II randomized controlled trial of nicotinamide for skin cancer chemoprevention in renal transplant recipients'.
Topics: Chemoprevention; Humans; Kidney Transplantation; Niacinamide; Skin Neoplasms; Transplant Recipients | 2017 |
Authors' response to a reply to 'A phase II randomized controlled trial of nicotinamide for skin cancer chemoprevention in renal transplant recipients'.
Topics: Chemoprevention; Humans; Kidney Transplantation; Niacin; Niacinamide; Skin Neoplasms | 2017 |
Multiple squamous cell carcinomas of the skin after therapy with sorafenib combined with tipifarnib.
Topics: Aged; Antineoplastic Agents; Benzenesulfonates; Biopsy; Carcinoma, Renal Cell; Carcinoma, Squamous C | 2008 |
Sorafenib-induced eruptive melanocytic lesions.
Topics: Administration, Oral; Antineoplastic Agents; Benzenesulfonates; Biopsy; Carcinoma, Renal Cell; Diagn | 2008 |
A Kaposi's sarcoma complete clinical response after sorafenib administration.
Topics: Benzenesulfonates; Carcinoma, Renal Cell; Drug Administration Schedule; Follow-Up Studies; Humans; K | 2008 |
Searching for the Achilles' heel of melanoma cells: new treatment modalities.
Topics: Animals; Antineoplastic Agents; Apoptosis; Benzenesulfonates; Clinical Trials as Topic; Enzyme Inhib | 2008 |
Follicular hyperplasia on the face subsequent to therapy with sorafenib. A new skin side effect.
Topics: Aged, 80 and over; Antineoplastic Agents; Benzenesulfonates; Humans; Hyperplasia; Lung Neoplasms; Ma | 2009 |
[Eruptive nevi associated with sorafenib treatment].
Topics: Adult; Aged; Antineoplastic Agents; Benzenesulfonates; Humans; Male; Middle Aged; Nevus; Niacinamide | 2008 |
Targeting metastatic melanoma.
Topics: Antibodies, Monoclonal; Antigens, CD; Antineoplastic Agents; Benzenesulfonates; Cancer Vaccines; Cli | 2008 |
Unexpected autocrine role of vascular endothelial growth factor in squamous cell carcinoma.
Topics: Aneuploidy; Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Benzenesulfonates; B | 2009 |
Cutaneous squamous cell carcinoma and inflammation of actinic keratoses associated with sorafenib.
Topics: Aged; Benzenesulfonates; Carcinoma, Renal Cell; Carcinoma, Squamous Cell; Drug Eruptions; Female; Hu | 2009 |
Molecular determinants of melanoma malignancy: selecting targets for improved efficacy of chemotherapy.
Topics: Animals; Antineoplastic Agents; Benzenesulfonates; Biomarkers, Tumor; Dacarbazine; Drug Delivery Sys | 2009 |
Multiple colon ulcerations, perforation and death during treatment of malignant melanoma with sorafenib.
Topics: Abdomen, Acute; Aged; Antineoplastic Agents; Benzenesulfonates; Colectomy; Colonic Diseases; Diarrhe | 2009 |
Keratoacanthomas and squamous cell carcinomas in patients receiving sorafenib.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Squamous Cell; | 2009 |
Eruptive keratoacanthoma-type squamous cell carcinomas in patients taking sorafenib for the treatment of solid tumors.
Topics: Adult; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Squamous Cell; Female; Humans; Keratoaca | 2009 |
The histologic spectrum of epithelial neoplasms induced by sorafenib.
Topics: Aged; Antineoplastic Agents; Benzenesulfonates; Biopsy; Carcinoma, Renal Cell; Carcinoma, Squamous C | 2009 |
Sorafenib induces partial response in metastatic medullary thyroid carcinoma.
Topics: Adult; Antineoplastic Agents; Benzenesulfonates; Bone Neoplasms; Carcinoma, Neuroendocrine; Humans; | 2010 |
C-Raf is associated with disease progression and cell proliferation in a subset of melanomas.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Benzenesulfonates; Cell Line, Tumor; Cell Proliferation; | 2009 |
Complete remission in a patient with multifocal metastatic cutaneous angiosarcoma with a combination of paclitaxel and sorafenib.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Head and Neck Neoplasms; He | 2010 |
Clinical responses observed with imatinib or sorafenib in melanoma patients expressing mutations in KIT.
Topics: Adult; Aged; Antineoplastic Agents; Benzamides; Benzenesulfonates; Female; Humans; Imatinib Mesylate | 2010 |
The farnesyl transferase inhibitor lonafarnib inhibits mTOR signaling and enforces sorafenib-induced apoptosis in melanoma cells.
Topics: Antineoplastic Agents; Apoptosis; Basic Helix-Loop-Helix Transcription Factors; Benzenesulfonates; C | 2011 |
Improved detection of regional melanoma metastasis using 18F-6-fluoro-N-[2-(diethylamino)ethyl] pyridine-3-carboxamide, a melanin-specific PET probe, by perilesional administration.
Topics: Animals; Fluorine Radioisotopes; Lymphatic Metastasis; Melanins; Melanoma; Mice; Mice, Inbred C57BL; | 2011 |
Regional squamous cell carcinomas following systemic sorafenib therapy and isolated limb infusion for regionally advanced metastatic melanoma of the limb.
Topics: Aged; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Squamous Cell; Drug Administration Routes | 2010 |
Invasive squamous cell carcinoma and sorafenib in a black patient.
Topics: Antineoplastic Agents; Benzenesulfonates; Black People; Carcinoma, Hepatocellular; Carcinoma, Squamo | 2011 |
Measurements of tumor cell autophagy predict invasiveness, resistance to chemotherapy, and survival in melanoma.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Autophagy; Benzenesulfonates; Cell Count; C | 2011 |
[Squamous cell carcinoma in a patient receiving sorafenib].
Topics: Antineoplastic Agents; Benzenesulfonates; Biopsy; Carcinoma, Renal Cell; Carcinoma, Squamous Cell; C | 2011 |
Eruptive squamous cell carcinomas with keratoacanthoma-like features in a patient treated with sorafenib.
Topics: Aged, 80 and over; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Carcinoma, S | 2011 |
Design, synthesis, and antiproliferative activity of new 1H-pyrrolo[3,2-c]pyridine derivatives against melanoma cell lines.
Topics: Animals; Antineoplastic Agents; Benzenesulfonates; Cell Line, Tumor; Cell Proliferation; Drug Screen | 2011 |
[News on melanoma from the 2010 Dermatology Days in Paris].
Topics: Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Biomarkers, Tumor; Chemotherapy, | 2011 |
Fibroblast growth factor receptors as therapeutic targets in human melanoma: synergism with BRAF inhibition.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Benzenesulfonates; | 2011 |
RAS mutations are associated with the development of cutaneous squamous cell tumors in patients treated with RAF inhibitors.
Topics: Adult; Aged; Aged, 80 and over; Benzenesulfonates; Carcinoma, Squamous Cell; Female; Gene Expression | 2012 |
Skin tumors induced by sorafenib; paradoxic RAS-RAF pathway activation and oncogenic mutations of HRAS, TP53, and TGFBR1.
Topics: Adult; Aged; Antineoplastic Agents; Benzenesulfonates; Biomarkers, Tumor; Blotting, Western; Carcino | 2012 |
Partial response of angiosarcoma of the scalp to sorafenib: association with decreased expression of vascular endothelial growth factors and their receptors.
Topics: Antineoplastic Agents; Head and Neck Neoplasms; Hemangiosarcoma; Humans; Male; Middle Aged; Niacinam | 2012 |
Effects of employing a ¹⁰B-carrier and manipulating intratumour hypoxia on local tumour response and lung metastatic potential in boron neutron capture therapy.
Topics: Animals; Antineoplastic Agents; Borohydrides; Boron Neutron Capture Therapy; Bromodeoxyuridine; Cell | 2012 |
Painful leg mass.
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Hospice Care; Humans; Kidney Neopla | 2012 |
Multiple cutaneous metastatic chordomas from the sacrum.
Topics: Aged; Antineoplastic Agents; Benzenesulfonates; Bone Neoplasms; Chordoma; Female; Humans; Niacinamid | 2012 |
Angiosarcoma of the scalp successfully treated with a single therapy of sorafenib.
Topics: Aged; Antineoplastic Agents; Benzenesulfonates; Female; Head and Neck Neoplasms; Hemangiosarcoma; Hu | 2012 |
Synthetic lethal screening with small-molecule inhibitors provides a pathway to rational combination therapies for melanoma.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cell Death; Cell Line, Tumor; | 2012 |
Nicotinamide enhances repair of ultraviolet radiation-induced DNA damage in human keratinocytes and ex vivo skin.
Topics: 8-Hydroxy-2'-Deoxyguanosine; Cell Line; Deoxyguanosine; DNA; DNA Damage; DNA Glycosylases; DNA Repai | 2013 |
Expression of angiogenesis-related gene profiles and development of resistance to tyrosine-kinase inhibitor in advanced renal cell carcinoma: characterization of sorafenib-resistant cells derived from a cutaneous metastasis.
Topics: Aneuploidy; Carcinoma, Renal Cell; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; | 2013 |
UV radiation-induced immunosuppression is greater in men and prevented by topical nicotinamide.
Topics: Administration, Topical; Adult; Apoptosis; Complement System Proteins; Energy Metabolism; Erythema; | 2008 |
Complete response in a cutaneous facial metastatic nodule from renal cell carcinoma after hypofractionated radiotherapy.
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Facial Neoplasms; Humans; Interleuk | 2007 |
Combined inhibition of MAPK and mTOR signaling inhibits growth, induces cell death, and abrogates invasive growth of melanoma cells.
Topics: Androstadienes; Apoptosis; Benzenesulfonates; Butadienes; Cell Line, Tumor; Cell Proliferation; Chro | 2008 |
Bowel perforation after radiotherapy in a patient receiving sorafenib.
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Combined Modality Therapy; Female; | 2008 |
Combination of fractionated irradiation with nicotinamide and carbogen in R1H-tumours of the rat and its pulmonary metastases.
Topics: Animals; Carbon Dioxide; Combined Modality Therapy; Disease Models, Animal; Dose Fractionation, Radi | 1997 |
Prevention of photoimmunosuppression and photocarcinogenesis by topical nicotinamide.
Topics: Administration, Topical; Adoptive Transfer; Animals; Antibodies, Monoclonal; Carcinoma, Squamous Cel | 1997 |
The effect of combined nicotinamide and carbogen treatments in human tumour xenografts: oxygenation and tumour control studies.
Topics: Administration, Inhalation; Animals; Carbon Dioxide; Cell Hypoxia; Drug Combinations; Glioblastoma; | 1998 |
Effects of nicotinamide on mouse skin tumor development and its mode of action.
Topics: Animals; Apoptosis; Female; Mice; Niacinamide; Ornithine Decarboxylase; Skin Neoplasms; Tetradecanoy | 1999 |
Photodynamic therapy with hypericin in a mouse P388 tumor model: vascular effects determine the efficacy.
Topics: Animals; Anthracenes; Blood Vessels; Dose-Response Relationship, Drug; Female; Fluorescein; Hydralaz | 2001 |
Nicotinamide and nicotinamide analogues as antitumor promoters in mouse skin.
Topics: 9,10-Dimethyl-1,2-benzanthracene; Aminobenzoates; Animals; Antineoplastic Agents; Benzamides; Benzoa | 1990 |
Urocanic acid in epidermal carcinogenesis.
Topics: Animals; Carcinoma, Squamous Cell; Humans; Imidazoles; Methylcholanthrene; Mice; Neoplasms, Experime | 1968 |